Biophytis expands patient recruitment for part II of COVA Study in France, Belgium

Article

Biophytis will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing its leading drug candidate as a potential treatment for acute respiratory failure linked to COVID-19.

Biophytis has announced that it will begin recruiting patients in France and Belgium for the second part of the COVA Study analyzing Sarconeos (BIO101), its leading drug candidate, as a potential treatment for acute respiratory failure linked to COVID-19.

Along with Regulatory Authorities in Brazil and the U.S. providing authorization for the start of part 2 clinical trials, authorization has also been obtained in France and Belgium to begin recruitment, according to a company news release.

This follows the completion of enrollment for part 1 of the study, which includes 50 participants.

The COVA Study is a global, multi-center, double-blind, placebo-controlled, two-part phase 2-3 study assessing Sarconeos (BIO101), administered orally, in patients aged 45 and older who have been hospitalized with severe respiratory manifestations of COVID-19, the release stated.

The first part of the study targets preliminary data on the safety, tolerability and activity of Sarconeos (BIO101) in the trial’s participants. Interim analysis is tentatively expected later in this first quarter of this year, pending COVID-19 related delays or pandemic impacts, according to the company.

The second part of the COVA Study includes a phase 3 pivotal randomized study investigating the safety, efficacy of Sarconeos (BIO101) in the respiratory function of 310 COVID-19 patients (including the 50 patients from part 1 of the study), the company states.

Complete results from both part 1 and part 2 of the study are expected in the second quarter of this year, pending any COVID-19-related delays, patient enrollment issues, or other interruptions.


Read more COVID-19 coverage here


Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.